Hospitalisation for heart failure and death in new users of SGLT-2 inhibitors in patients with and without cardiovascular disease: the CVDREAL study

被引：0
|
作者：
Cavender, M. A. [1 ]
Norhammar, A. [2 ]
Birkeland, K. I. [3 ,4 ]
Jorgensen, M. E. [5 ]
Wilding, P. [6 ]
Khunti, K. [7 ]
Fu, A. Z. [8 ]
Bodegard, J. [9 ]
Blak, B. [10 ]
Wittbrodt, E. T. [11 ]
Thuresson, M. [12 ]
Fenici, P. [13 ]
Hammar, N. [2 ,14 ]
Kosiborod, M. [15 ,16 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
[2] Karolinska Inst, Stockholm, Sweden
[3] Univ Oslo, Oslo, Norway
[4] Oslo Univ Hosp, Oslo, Norway
[5] Steno Diabet Ctr Copenhagen, Gentofte, Denmark
[6] Inst Ageing & Chron Dis, Liverpool, Merseyside, England
[7] Univ Leicester, Leicester, Leics, England
[8] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[9] AstraZeneca, Oslo, Norway
[10] AstraZeneca, Luton, Beds, England
[11] AstraZeneca, Wilmington, DE USA
[12] Statisticon AB, Uppsala, Sweden
[13] AstraZeneca, Cambridge, England
[14] AstraZeneca Gothenburg, Molndal, Sweden
[15] St Lukes Mid Amer Heart Inst, Kansas City, MO USA
[16] Univ Missouri Kansas City, Kansas City, MO USA
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
88
引用
收藏
页码：S41 / S41
页数：1
相关论文
共 50 条
  • [21] SGLT-2 Inhibitors: Fighting Cardiovascular Disease Mortality in Diabetes
    Ghaffar, Zunaira Abdul
    Anwar, Shahzad
    Rizvi, Syed Wajih
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2019, 29 (02): : 195 - 195
  • [22] SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?
    Mahmoud Al Rifai
    L. Kristin Newby
    Ajith P. Nair
    Arunima Misra
    Joseph G. Rogers
    Savitri Fedson
    Salim S. Virani
    Current Atherosclerosis Reports, 2022, 24 : 627 - 634
  • [23] SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?
    Al Rifai, Mahmoud
    Newby, L. Kristin
    Nair, Ajith P.
    Misra, Arunima
    Rogers, Joseph G.
    Fedson, Savitri
    Virani, Salim S.
    CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (08) : 627 - 634
  • [24] SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes
    Noergaard, C.
    Torp-Pedersen, C.
    Vestergaard, P.
    Wong, N.
    Gerds, T.
    Starkopf, L.
    Bonde, A.
    Fosbol, E.
    Kober, L.
    Lee, C.
    EUROPEAN HEART JOURNAL, 2019, 40 : 56 - 56
  • [25] Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?
    Singh, Awadhesh Kumar
    Singh, Ritu
    Misra, Anoop
    JOURNAL OF DIABETES, 2021, 13 (07) : 596 - 600
  • [26] Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials
    Lu, Yuan
    Li, Fei
    Fan, Yong
    Yang, Yu
    Chen, Minglong
    Xi, Jue
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2021, 87 : 20 - 28
  • [27] Safety of SGLT-2 inhibitors in the management of heart failure in the adult congenital heart disease patient population
    Kheiwa, Ahmed
    Ssembajjwe, Brian
    Chatta, Payush
    Nageotte, Stephen
    Abramov, Dmitry
    INTERNATIONAL JOURNAL OF CARDIOLOGY CONGENITAL HEART DISEASE, 2024, 15
  • [28] How Do SGLT-2 Inhibitors Work to Prevent Heart Failure?
    Vaduganathan, Muthiah
    Claggett, Brian L.
    Solomon, Scott D.
    JACC-HEART FAILURE, 2020, 8 (01) : 67 - 69
  • [29] SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives
    Garla, Vishnu Vardhan
    Butler, Javed
    Lien, Lillian F.
    CURRENT CARDIOLOGY REPORTS, 2021, 23 (06)
  • [30] SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives
    Vishnu Vardhan Garla
    Javed Butler
    Lillian F. Lien
    Current Cardiology Reports, 2021, 23
12345